| Metric | Value ($ M) | Q3 FY25 |
|---|---|---|
| Revenue | 83.90 | 10.7% |
| Total Income | 83.90 | 10.7% |
| Expenditure | 84.36 | 0.8% |
| PBT | — | |
| Net Profit | 2.88 | 69.8% |
| OPM | -0.55% | 11.49pp |
| NPM | 3.43% | 6.73pp |
| EPS | 0.02 | 66.7% |
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
05 Nov 2026 · 5 Nov, 2:53 am
Summary
Adaptive Biotechnologies reported third quarter 2026 financial results, achieving total company profitability ahead of expectations with adjusted EBITDA of $14.3 million. While total revenue decreased 11% year-over-year to $83.9 million, excluding the Genentech Agreement, revenue increased by 39%. The company saw significant growth in its MRD business, with MRD revenue up 28% year-over-year to $72.6 million and clonoSEQ® tests increasing by 46%. Management raised the full-year 2026 MRD revenue guidance to $276 million-$286 million, reflecting strong momentum and the increasing need for MRD testing.
Key Highlights
- 1
Adaptive Biotechnologies reported total company profitability ahead of expectations in Q3 2026, with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million.
- 2
MRD revenue increased 28% year-over-year to $72.6 million in the third quarter of 2026, and 44% excluding milestones.
- 3
The company delivered 39,587 clonoSEQ® tests in Q3 2026, representing a 46% increase compared to the third quarter of 2025.
- 4
Total revenue for the third quarter of 2026 was $83.9 million, a decrease of 11% from the prior year, but revenue increased 39% excluding the Genentech Agreement.
- 5
Adaptive Biotechnologies raised its full year 2026 MRD revenue guidance to a range of $276 million to $286 million, indicating 30% to 35% annual growth.
- 6
Net income for the third quarter of 2026 was $2.8 million, compared to $9.5 million in the same period of 2025.
Management Comments
Chad Robins
Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.
Informational and educational content only. Not investment advice.